Kaushik Rajaram

Dr. Kaushik Rajaram

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
AMAarcha Shanmugha Mary
Aarcha Shanmugha Mary
VRVikram Srinivasa Raghavan
Vikram Srinivasa Raghavan
SKSirisha Kagula
Sirisha Kagula
VKVinodhini Krishnakumar
Vinodhini Krishnakumar
MKMeganathan Kannan
Meganathan Kannan
KRKaushik Rajaram
Kaushik Rajaram

10 November 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
NKNashath Kalangadan
Nashath Kalangadan
AMAarcha Shanmugha Mary
Aarcha Shanmugha Mary
KMKaushik Mani
Kaushik Mani
BNBiplab Nath
Biplab Nath
JKJayalalitha Kondapalli
Jayalalitha Kondapalli
KRKaushik Rajaram
Kaushik Rajaram

13 April 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MTMuneeswaran Thillaichidambaram
Muneeswaran Thillaichidambaram
MMMuthuchamy Maruthupandy
Muthuchamy Maruthupandy
AMAarcha Shanmugha Mary
Aarcha Shanmugha Mary
TVThirumalaiswamy Vennila
Thirumalaiswamy Vennila
KRKaushik Rajaram
Kaushik Rajaram
FQFranck Quero
Franck Quero

2 November 2024 in Heliyon
Verified
Journal Article
Open access
AMAarcha Shanmugha Mary
Aarcha Shanmugha Mary
NKNashath Kalangadan
Nashath Kalangadan
JPJohn Prakash
John Prakash
SSSrivignesh Sundaresan
Srivignesh Sundaresan
SGSutharsan Govindarajan
Sutharsan Govindarajan
KRKaushik Rajaram
Kaushik Rajaram
Bacteriophages, the natural predators of bacteria, are incredibly potent candidates to counteract antimicrobial resistance (AMR). However, the rapid development of phage-resistant mutants challenges the potential of phage therapy. Understanding the mechanisms of bacterial adaptations to phage predation is crucial for phage-based prognostic applications. Phage cocktails and combinatorial therapy, using optimized dosage patterns of antibiotics, can negate the development of phage-resistant mutations and prolong therapeutic efficacy. In this study, we describe the characterization of a novel bacteriophage and the physiology of phage-resistant mutant developed during infection. M12PA is a P. aeruginosa-infecting bacteriophage with Myoviridae morphology. We observed that prolonged exposure of P. aeruginosa to M12PA resulted in the selection of phage-resistant mutants. Among the resistant mutants, pyomelanin-producing mutants, named PA-M, were developed at a frequency of 1 in 16. Compared to the wild-type, we show that PA-M mutant is severely defective in virulence properties, with altered motility, biofilm formation, growth rate, and antibiotic resistance profile. The PA-M mutant exhibited reduced pathogenesis in an allantoic-infected chick embryo model system compared to the wild-type. Finally, we provide evidence that combinatory therapy, combining M12PA with antibiotics or other phages, significantly delayed the emergence of resistant mutants. In conclusion, our study highlights the potential of combinatory phage therapy to delay the development of phage-resistant mutants and enhance the efficacy of phage-based treatments against P. aeruginosa.

19 August 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAbishek Mani
Abishek Mani
AMAarcha Shanmugha Mary
Aarcha Shanmugha Mary
NKNashath Kalangadan
Nashath Kalangadan
SSSrivignesh Sundaresan
Srivignesh Sundaresan
SGSomnath Ghosh
Somnath Ghosh
KRKaushik Rajaram
Kaushik Rajaram
Humanity could descend into a pre-antibiotic world as a result of antimicrobial resistance (AMR). Phage defenses are considered “vintage heroes” in the battle against multidrug-resistant (MDR) bacteria. However, phage resistance continues to evolve, necessitating alternative strategies. A potential solution is combining phages with antimicrobials like silver nanoparticles (AgNPs) to enhance the phage therapy. This study focuses on a combination therapy using Bauhinia variegata L.-mediated AgNPs and Pseudomonas phage M12PA to target multidrug-resistant (MDR) Pseudomonas aeruginosa. The antibacterial properties of this combination were evaluated through comprehensive characterizations and assays. As a proof of concept, the AgNP-phage combination delayed phage resistance by 6–12 h, reduced mutation, and enhanced antibacterial efficiency. Anti-biofilm activity improved by ~ 40% compared to AgNPs alone at sub-inhibitory concentrations. AgNPs and phages have demonstrated excellent compatibility, and the phage titer did not drop noticeably over 30 days. Biocompatibility assessments, including cell viability and hemolysis assays, highlighted the safety of biosynthesized AgNPs. Wound healing efficacy was also demonstrated in mouse fibroblast cells and an in ovo angiogenesis model. This study underscores the efficiency of phage-AgNPs synergy to be a potential therapeutic approach for MDR bacterial wound infection, showing effective anti-biofilm activity, delayed phage resistance, and minimal toxicity.